…
Quantum-Si incorporated, a life sciences company, develops proprietary, universal, and single-molecule detection platform applied to proteomics to enable next-gen protein sequencing (NGPS). The company offers Platinum and Platinum Pro NGPS instruments for single-molecule, amino acid level resolution, and automated data analysis; library preparation kits to prepare a customer's protein sample for sequencing; and sequencing kits, which contain the reagents and consumables used to perform NGPS. It also provides Platinum analysis software, a cloud-based solution that automates data analysis workflows and visualizes the sequencing results. The company was founded in 2013 and is headquartered in Branford, Connecticut.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -101.28M | -100.95M | -95.96M | -132.44M | -94.99M |
| Net income | -101.34M | -101.01M | -95.96M | -141.04M | -88.95M |
| Selling general administrative | 44.75M | 50.53M | 42.81M | 42.30M | 46.38M |
| Selling and marketing expenses | - | - | 0.40M | - | 3.96M |
| Gross profit | 1.15M | 1.60M | 0.49M | - | - |
| Reconciled depreciation | 4.45M | 4.60M | 3.86M | 2.58M | 1.04M |
| Ebit | -97.36M | -100.95M | -95.96M | -123.84M | -96.91M |
| Ebitda | -92.91M | -96.35M | -91.80M | -134.50M | -101.91M |
| Depreciation and amortization | 4.45M | 4.60M | 4.16M | -10.66M | -5.00M |
| Non operating income net other | - | - | - | -8.60M | 1.92M |
| Operating income | -97.36M | -108.58M | -111.17M | -123.84M | -96.91M |
| Other operating expenses | 99.80M | 111.63M | 112.25M | 114.36M | 96.91M |
| Interest expense | - | - | 0.00M | 13.25M | 0.01M |
| Tax provision | 0.06M | 0.06M | 0.00M | 0.00M | 0.00M |
| Interest income | 8.96M | 9.64M | 0.46M | - | - |
| Net interest income | 8.96M | 9.64M | 0.46M | 0.00M | -0.01M |
| Non recurring | - | - | - | 9.48M | - |
| Income tax expense | 0.06M | 0.06M | 0.00M | 8.60M | -6.04M |
| Total revenue | 2.44M | 3.06M | 1.08M | 0.00M | 0.00M |
| Total operating expenses | 98.51M | 110.18M | 111.66M | 114.36M | 96.91M |
| Cost of revenue | 1.28M | 1.46M | 0.59M | - | - |
| Total other income expense net | -3.92M | 7.62M | 15.21M | -8.60M | 1.92M |
| Net income from continuing ops | -101.34M | -101.01M | -107.05M | -132.44M | -94.99M |
| Net income applicable to common shares | - | - | - | -132.44M | -94.99M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 245.61M | 247.87M | 298.25M | 391.49M | 503.23M |
| Intangible assets | - | - | 0.53M | - | - |
| Other current assets | 9.19M | 3.01M | 4.26M | 6.87M | 5.87M |
| Total liab | 25.38M | 32.45M | 26.63M | 32.78M | 26.19M |
| Total stockholder equity | 220.23M | 215.42M | 271.62M | 358.71M | 477.03M |
| Deferred long term liab | - | - | - | 1.00M | 7.24M |
| Other current liab | 16.07M | 11.22M | 6.76M | 10.43M | 0.02M |
| Common stock | 0.02M | 0.02M | 0.01M | 0.01M | 0.01M |
| Capital stock | 0.02M | 0.02M | 0.01M | 0.01M | 0.01M |
| Retained earnings | -697.98M | -596.64M | -495.63M | -399.67M | -267.23M |
| Other liab | - | - | - | 1.00M | 7.45M |
| Good will | - | - | - | 0.00M | 9.48M |
| Other assets | - | - | 0.00M | 0.70M | 0.69M |
| Cash | 21.64M | 49.24M | 133.86M | 84.32M | 35.78M |
| Total current liabilities | 23.02M | 18.19M | 11.61M | 15.71M | 11.53M |
| Current deferred revenue | 3.49M | - | 1.52M | - | 7.25M |
| Net debt | -17.47M | -36.29M | -118.56M | -66.87M | -27.71M |
| Short term debt | 1.84M | 3.70M | 1.57M | 1.37M | 0.86M |
| Short long term debt total | 4.17M | 12.95M | 15.30M | 17.45M | 8.08M |
| Other stockholder equity | 918.19M | 812.00M | 767.24M | 758.37M | 744.25M |
| Property plant equipment | - | - | - | 16.85M | 15.88M |
| Total current assets | 175.86M | 218.01M | 266.31M | 358.18M | 477.17M |
| Long term investments | 52.85M | 0.00M | - | - | - |
| Net tangible assets | - | - | - | 358.71M | 467.55M |
| Short term investments | 141.27M | 160.36M | 123.88M | 266.99M | 435.52M |
| Net receivables | 0.56M | 1.33M | 0.37M | 0.21M | 0.87M |
| Inventory | 3.20M | 4.07M | 3.94M | - | - |
| Accounts payable | 1.62M | 1.93M | 1.77M | 3.90M | 3.39M |
| Accumulated other comprehensive income | -0.01M | 0.04M | - | - | -503.23M |
| Common stock total equity | - | - | - | 0.01M | 0.01M |
| Retained earnings total equity | - | - | - | -399.67M | -267.23M |
| Non currrent assets other | 0.23M | 0.81M | 0.69M | 0.70M | 0.69M |
| Non current assets total | 69.75M | 29.86M | 31.94M | 33.30M | 26.05M |
| Capital lease obligations | 4.17M | 12.95M | 15.30M | 17.45M | 8.08M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -25.80M | -32.67M | 107.86M | 147.93M | -440.54M |
| Change to liabilities | - | - | - | 4.73M | 5.21M |
| Total cashflows from investing activities | -28.32M | -32.67M | 143.43M | 137.19M | -450.94M |
| Net borrowings | - | - | 0.00M | - | -1.75M |
| Total cash from financing activities | 95.42M | 35.88M | 0.15M | 1.91M | 516.62M |
| Change to operating activities | - | - | - | 3.58M | 0.76M |
| Net income | -101.34M | -101.01M | -95.96M | -132.44M | -94.99M |
| Change in cash | -27.60M | -84.62M | 49.54M | 48.53M | -1.12M |
| Begin period cash flow | 49.24M | 133.86M | 84.32M | 35.78M | 36.91M |
| End period cash flow | 21.64M | 49.24M | 133.86M | 84.32M | 35.78M |
| Total cash from operating activities | -94.72M | -87.80M | -94.04M | -90.56M | -66.81M |
| Issuance of capital stock | 93.51M | 34.79M | 0.00M | 0.00M | 512.79M |
| Depreciation | 4.45M | 4.60M | 4.16M | 2.58M | 1.04M |
| Other cashflows from investing activities | - | -0.06M | -0.76M | - | -4.63M |
| Change to inventory | -2.01M | 4.34M | 0.29M | - | - |
| Change to account receivables | 0.63M | -1.09M | -0.37M | - | - |
| Sale purchase of stock | - | - | - | 2.76M | 5.61M |
| Other cashflows from financing activities | 0.00M | 1.09M | 0.15M | -0.85M | 5.61M |
| Change to netincome | - | - | - | 14.71M | 25.67M |
| Capital expenditures | 2.52M | 4.58M | 5.27M | 10.74M | 5.76M |
| Cash flows other operating | - | - | - | 19.86M | -3.74M |
| Cash and cash equivalents changes | - | - | - | 48.53M | -1.12M |
| Change in working capital | -4.58M | 4.64M | -3.19M | 4.30M | 1.47M |
| Stock based compensation | 10.77M | 8.89M | 8.52M | 11.21M | 24.92M |
| Other non cash items | -4.03M | -4.92M | -7.55M | 23.79M | 0.04M |
| Free cash flow | -97.23M | -92.38M | -99.31M | -101.30M | -72.58M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| QSI QuantumSi Inc |
-0.10 7.82% |
1.17 | - | - | 98.19 | 0.88 | 31.28 | 0.63 |
| ABT Abbott Laboratories |
-0.71 0.65% |
108.58 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
0.28 0.28% |
101.89 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-2.16 0.68% |
316.63 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
- -% |
47.31 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Quantum-Si incorporated, a life sciences company, develops proprietary, universal, and single-molecule detection platform applied to proteomics to enable next-gen protein sequencing (NGPS). The company offers Platinum and Platinum Pro NGPS instruments for single-molecule, amino acid level resolution, and automated data analysis; library preparation kits to prepare a customer's protein sample for sequencing; and sequencing kits, which contain the reagents and consumables used to perform NGPS. It also provides Platinum analysis software, a cloud-based solution that automates data analysis workflows and visualizes the sequencing results. The company was founded in 2013 and is headquartered in Branford, Connecticut.
29 Business Park Drive, Branford, CT, United States, 06405
866 688 7374
145
| Name | Title | Year Born |
|---|---|---|
| Dr. Jonathan M. Rothberg Ph.D. | Founder & Exec. Chairman | 1964 |
| Ms. Claudia Napal Drayton | Chief Financial Officer | 1968 |
| Dr. Christian Lapointe J.D., Ph.D. | Gen. Counsel & Corp. Sec. | 1972 |
| Dr. Michael P. McKenna Ph.D. | Exec. VP of Product Devel. & Operations | 1962 |
| Mr. Jeffrey Alan Hawkins | CEO & Director | 1978 |
| Dr. Patrick Schneider Ph.D. | Pres & COO | NA |
| Mr. Todd Rearick | Chief Technology Officer | NA |
| Mr. Juan Esteban Avendano | VP of Investor Relations | NA |
| Dr. Jonathan M. Rothberg Ph.D. | Founder & Executive Chairman | 1964 |
| Mr. Jeffrey Alan Hawkins | President, CEO & Director | 1978 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.